Key result
Early reperfusion with t-PA YM866 (0.1 mg/kg) 30 min after occlusion improved ventricular function and cardiac hypertrophy, whereas late reperfusion at 3 h only inhibited hypertrophy in dogs.
Why the study?
Does early or late reperfusion with t-PA YM866 improve ventricular function and cardiac hypertrophy in dogs with coronary artery thrombi?
Does early or late reperfusion with t-PA YM866 improve ventricular function and cardiac hypertrophy in dogs with coronary artery thrombi?
Answers are grounded in this paper and cite their sources.
Early reperfusion with t-PA improves ventricular function and limits infarction, whereas late reperfusion only inhibits cardiac hypertrophy without improving function in a canine model of coronary thrombosis.
Subacute prognosis of cardiac function after thrombolysis with a modified tissue-type plasminogen activator (t-PA) YM866 was determined in dogs with coronary artery thromboses induced by injection of a thrombin, fibrinogen and autogenous blood mixture. The left ventricular ejection fraction (LVEF) decreased 30 min after occlusion and had not improved 1 week later. Examination after sacrifice revealed myocardial infarction as well as increases in both the left ventricular myocardial area and heart mass. Occluded coronary arteries reperfused by YM866 (0.1 mg kg(-1) i.v.) treatment 30 min after occlusion, by contrast, had improved LVEF and inhibited myocardial infarction development. In addition, the left ventricular myocardial area and heart mass were significantly reduced compared with the vehicle control group 1 week after administration. Although occluded coronary arteries reperfused by YM866 (0.1 mg kg(-1) i.v.) treatment 3 h after occlusion did not show an improvement in the LVEF or inhibition of myocardial infarction development, the left ventricular myocardial area and heart mass decreased significantly compared with the vehicle control group 1 week after administration. In conclusion, early reperfusion by t-PA treatment 30 min after occlusion improved the ventricular function and cardiac hypertrophy, whereas late reperfusion by t-PA treatment 3 h after occlusion did not improve the ventricular function but did inhibit hypertrophy in dogs with coronary artery thrombi.
No takes yet. Share an insight, caveat, or question.
Suzuki et al. (2000) studied Coronary artery thrombosis. Modified tissue-type plasminogen activator (t-PA) YM866 vs. Vehicle control was evaluated on Cardiac function (LVEF), myocardial infarction development, left ventricular myocardial area, and heart mass. Early reperfusion with t-PA YM866 (0.1 mg/kg) 30 min after occlusion improved ventricular function and cardiac hypertrophy, whereas late reperfusion at 3 h only inhibited hypertrophy in dogs.
Synapse has enriched 10 related papers. Consider them for comparative context: